Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
|
|
- Silas Malone
- 6 years ago
- Views:
Transcription
1 Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo, MD; Saumil H. Trivedi, MD; Joseph N. Burzynski, MD; and Neil W. Schluger, MD Background: The tuberculin skin test (TST) has a low specificity in the setting of bacille Calmette-Guérin (BCG) vaccination. Interferon- release assays (IGRAs) appear to be more specific but have not been validated in this population under routine clinical conditions. We sought to validate the routine clinical use of the T-SPOT.TB test (Oxford Immunotec; Oxford, UK), an IGRA, in a predominantly foreign-born population with a high rate of BCG vaccination. Methods: We compared the TST and the T-SPOT.TB test in 96 subjects at a New York City Department of Health tuberculosis clinic. We aimed to determine which test better predicted being a close contact of a case of active tuberculosis, a surrogate for latent tuberculosis infection. Results: A positive T-SPOT.TB test result was strongly associated with being a close contact of a case of active tuberculosis after adjustment for potential confounders (adjusted odds ratio, 2.9; 95% confidence interval, 1.1 to 7.3; p 0.03). A positive TST result was associated with being a contact only in subjects without BCG vaccination (p 0.02). The T-SPOT.TB test was more specific for being a close contact than the TST (p < 0.001). Specificity in BCG-vaccinated subjects was 3% for the TST compared with 70% for the T-SPOT.TB test (p < 0.001). Conclusions: The T-SPOT.TB test is superior in routine clinical use to the TST for identifying high-risk individuals among foreign-born populations with high rates of BCG vaccination. (CHEST 2008; 133: ) Key words: infection; interferon; tuberculosis; tuberculosis testing Abbreviations: BCG bacille Calmette-Guérin; CDC Centers for Disease Control and Prevention; CI confidence interval; DOHMH Department of Health and Mental Hygiene; IGRA interferon- release assay; LTBI latent tuberculosis infection; QFT QuantiFERON-TB Gold; TST tuberculin skin test Screening and treatment for latent tuberculosis infection (LTBI) are essential components of the strategy for reducing and eliminating tuberculosis in the United States. Current guidelines stress the targeting of screening and treatment to at-risk populations, which include both close contacts of cases of active tuberculosis and recent immigrants from high-prevalence countries. 1 These immigrants are of particular importance because more than one half of tuberculosis cases in the United States occur in this population, and strong evidence exists that most cases result from reactivation of latent infection. 2 LTBI is usually diagnosed by the tuberculin skin test (TST). Confounding by bacille Calmette-Guérin (BCG) vaccination (especially when administered after 1 year of age 3 ) is a significant limitation of skin testing. 4 Because the majority of individuals at high risk for LTBI, and by extension active tuberculosis, in the developed world have come from countries where they are vaccinated with BCG, the TST is least reliable and most problematic in those most in need of screening. Studies of LTBI in foreign-born patients, as diagnosed using the TST, indicate a very high frequency of positive results, yet active tuberculosis will develop in very few of those with a diagnosis made using the TST. It is likely that many of these test results are falsely positive due to BCG vaccination. Treatment of all such individuals is costly, carries a risk of significant side effects, and is obviously futile in those who do not have LTBI to begin with. Tests more specific for LTBI would improve the cost- CHEST / 133 / 4/ APRIL,
2 effectiveness, safety, and overall effectiveness of screening and treatment programs. Interferon- release assays (IGRAs) detect T-cell responses to antigens, including ESAT-6 and CFP10, specific for Mycobacterium tuberculosis and notably absent from Mycobacterium bovis BCG. Consequently, IGRAs should offer greater specificity for LTBI than the TST, 5 and these tests should be of particular benefit in those who have received BCG. Current guidelines from the Royal College of Physicians of London recommend using the commercially available IGRAs, either the QuantiFERON-TB Gold (QFT) [Cellestis, Ltd; Victoria, Australia] or the T-SPOT.TB test (Oxford Immunotec; Oxford, UK), only in those patients with positive TST results. 6 Recommendations from the Centers for Disease Control and Prevention (CDC) written for the QFT allow for it to be used more broadly, in lieu of the TST in all circumstances in which the TST is currently used. 1 In the present study, we sought to validate the use of the T-SPOT.TB test as compared with the TST under routine clinical conditions in the United States. In an urban public health clinic setting, we studied a cohort that included both close contacts of cases of active tuberculosis and noncontacts, of whom most were recent immigrants with a high rate of BCG vaccination. Contact status was used as a surrogate for LTBI. We aimed to compare the use of the T-SPOT.TB test with the TST in detecting LTBI in high-risk individuals as well as discriminating LTBI from BCG vaccination. Specifically, we aimed to answer the following questions: first, what is the sensitivity of the T-SPOT.TB test for contact status as compared with the TST? Second, what is the specificity of the T- SPOT.TB test in this population, and how does it *From the Division of Pulmonary, Allergy, and Critical Care Medicine (Drs. Brodie, Lederer, Gallardo, Trivedi, and Schluger), Columbia University Medical Center; and New York City Department of Health and Mental Hygiene (Dr. Burzynski), Bureau of Tuberculosis Control, New York, NY. Equipment for this study was provided by Oxford Immunotec, Ltd, Oxford, UK. Dr. Brodie is supported in part by a grant from the Stony Wold- Herbert Fund, Inc. Dr. Schluger is supported in part by the National Institutes of Health/National Heart, Lung, and Blood Institute (K24 HL004074). Dr. Lederer is supported in part by grant RR from the National Institutes of Health. The authors have no financial or other potential conflicts of interests to disclose. Manuscript received July 23, 2007; revision accepted December 5, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Neil Schluger, MD, Columbia University Medical Center, 622 West 168th St, PH 8 East, Room 101, New York, NY 10032; ns311@columbia.edu DOI: /chest compare with the TST? And third, what are the odds of having a positive test result (either T-SPOT.TB test or TST) in contacts as compared with noncontacts? Study Subjects Methods and Materials This study was approved by the institutional review boards of the New York City Department of Health and Mental Hygiene (DOHMH) and the Columbia University Medical Center. All subjects provided written, informed consent. We enrolled 123 subjects from a New York City DOHMH tuberculosis clinic from September 8, 2005, through February 21, Those enrolled included contacts of cases of active tuberculosis ( contacts ) and subjects who were not contacts of patients with active tuberculosis ( noncontacts ) but who were administered a TST at the DOHMH for reasons other than contact status (primarily as a result of outside referral regardless of risk status). All cases of active tuberculosis were sputum culture positive for M tuberculosis. Contacts were identified by the DOHMH and classified according to their standardized protocol into close contacts (defined as 8 h of contact with a patient with active tuberculosis per week), and other than close contacts (defined as those with contact for 8 h/wk.) A TST was administered as part of the routine workup. Subjects with active tuberculosis were excluded. All TSTs were performed by the Mantoux technique using 5 tuberculin units. TSTs were administered and read by trained, experienced DOHMH personnel according to DOHMH protocol. A positive reaction to the TST was defined according to published CDC criteria that stratify results by risk groups. 7,8 Inclusion and Exclusion Criteria Subjects were 5 years old. Subjects with active tuberculosis or nontuberculous mycobacteria infection or who had previously been treated for LTBI, active tuberculosis, or nontuberculous mycobacteria were excluded. Subjects with known HIV infection were excluded. TST testing must have taken place within 6 months of enrollment and T-SPOT.TB testing. A history of a positive TST result 6 months prior to enrollment also led to the exclusion of the subject because they were not retested if previously positive. Study Procedure After consent was obtained, demographic information and medical history were recorded on a standard questionnaire. Race and ethnicity were self-identified. Subjects were considered to have a history of BCG vaccination if they came from a country where BCG is routinely administered and either reported a history of BCG or had a characteristic vaccination scar. All patient information remained anonymous, identified only by a unique patient code, and was stored in locked files. All blood samples were marked with the patient code and were not identifiable by any other means. Samples were kept at room temperature and processed in our laboratory within8hbyoneofthree technicians all of whom were trained to run the T-SPOT.TB test by the manufacturer. The T-SPOT.TB test was performed according to manufacturer specifications. Spots were counted manually with a magnifying glass, but final results were based on counts checked by an automated plate reader after shipment to the manufacturer, Oxford Immunotec, Ltd. Additional detail on the method is provided in an online data supplement. Assay results and ques- 870 Original Research
3 tionnaire data were entered into a clinical database. The study sponsor played no role in data collection, analysis, or interpretation and was not involved in the writing or submitting of this article for publication. Statistical Analysis Continuous variables were summarized by mean and SD. Categorical variables were summarized by frequency and percentage and compared using 2 tests. We used logistic regression to estimate odds ratios for the associations between contact status and TST or T-SPOT.TB test results. Statistically significant interaction terms (p 0.05) were retained in the model. Multivariate models included terms for BCG vaccination status, age, HIV status (negative or unknown), and race/ethnicity. In lieu of a true gold standard for the diagnosis of LTBI, we used tuberculosis exposure (ie, contact status) as the standard for determining the operating characteristics of the TST and the T-SPOT.TB test. The overall agreement,, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of each test as predictors of close contact status were estimated from contingency tables; p values 0.05 were considered statistically significant. Statistical software (SAS 9.1; SAS Institute; Cary, NC) was used for all analyses. Role of the Sponsor Oxford Immunotec Ltd. provided the required consumables including cell preparation tubes (Becton Dickinson; Franklin Lakes, NJ) and venipuncture systems, training in the use of the assay, the T-SPOT.TB assay kits, and automated plate reading. In addition, they paid a portion of the salary of one technician for 2 years. Excluded Subjects Results We enrolled 123 subjects, of whom 27 were excluded. Four subjects never returned to have their TST results read. Three subjects were identified after enrollment who had positive TST results 6 months prior, and a repeat TST was not done as per protocol. Two subjects were determined to be HIV positive. One subject had been previously treated for LTBI but did not recall this information until after enrollment. Disseminated M bovis infection was diagnosed in one patient. Phlebotomy was unsuccessful in two subjects. Eight subjects had indeterminate tests. Technical difficulties with the T-SPOT.TB test occurred in six subjects. Study Subjects The characteristics of the 96 subjects included in the study are presented in Table 1. Fifty-six subjects were close contacts. Among the close contacts, 52 subjects were exposed to patients with active tuberculosis who were themselves acid-fast bacilli smear positive. Three additional subjects were other than close contacts. Each had minimal contact with index active tuberculosis cases. Their TST results were 20 mm, 10 mm, and Table 1 Characteristics of Close Contacts and Control Subjects* Variables Close Contacts 0 mm, respectively. We conservatively chose to group these three subjects with our noncontact control subjects (control group). Age, gender, foreign birth, race/ ethnicity, and HIV status were similar between close contacts and control subjects. Among close contacts, 63% were TST positive, 45% were T-SPOT.TB test positive, and 68% were BCG vaccinated. Among control subjects, 78% were TST positive, 25% were T-SPOT.TB test positive, and 75% were BCG vaccinated. Agreement Between the T-SPOT.TB and TSTs Overall agreement between the T-SPOT.TB and the TST was 64% (95% confidence interval [CI], 54 to 74%), and was 0.33 (95% CI, 0.19 to 0.48). Among BCG-vaccinated subjects, overall agreement and were 56% (95% CI, 43 to 68%) and 0.22 (95% CI, 0.06 to 0.37), respectively. Among those not BCG vaccinated, overall agreement and were 82% (95% CI, 68 to 96%) and 0.64 (95% CI, 0.38 to 0.91), respectively. Both overall agreement and were significantly better among subjects without BCG vaccination compared to subjects with BCG vaccination (p 0.02 for each measure). Associations Between Contact Status and the Results of the T-SPOT.TB and TSTs Control Subjects Subjects 56 (58) 40 (42) Age, yr Gender Male 39 (70) 20 (50) Female 17 (30) 20 (50) Foreign birth 41 (73) 32 (80) Race/ethnicity Hispanic (all races) 34 (61) 23 (58) Non-Hispanic black 13 (23) 9 (23) Non-Hispanic white 8 (14) 5 (13) Non-Hispanic Asian 1 (2) 3 (8) T-SPOT.TB test result Positive 25 (45) 10 (25) Negative 31 (55) 30 (75) TST result Positive 35 (63) 31 (78) Negative 21 (38) 9 (23) TST size 13.5 (0 18.5) 14 (10 20) BCG Vaccinated 38 (68) 30 (75) Unvaccinated 18 (32) 10 (25) HIV Negative 29 (52) 26 (65) Unknown 27 (48) 14 (35) *Data are presented as No. (%), mean SD, and median (interquartile range). In univariate analyses, neither the T-SPOT.TB test nor the TST were significantly associated with contact CHEST / 133 / 4/ APRIL,
4 Table 2 Odds Ratios for a Positive Test Result Among Close Contacts vs Control Subjects Variables Odds Ratio 95% CI status (Table 2). However, after adjustment for age, HIV status (negative or unknown), BCG vaccination status, and race/ethnicity, being a close contact was strongly associated with a positive T-SPOT.TB test (adjusted odds ratio, 2.9; 95% CI, 1.1 to 7.4, p 0.03). In this model, BCG vaccination was not significantly associated with a positive T-SPOT.TB test (adjusted odds ratio, 1.5; 95% CI, 0.5 to 4.2; p 0.47). The association between TST result and contact status varied by BCG vaccination status (p for interaction). Among BCG-vaccinated subjects, close contacts were less likely than control subjects to have a positive TST (adjusted odds ratio, 0.1; 95% CI, 0.01 to 0.5; p 0.01). However, among subjects without BCG vaccination, close contacts were more likely than control to have a positive TST result (adjusted odds ratio, 9.1; 95% CI, 1.2 to 67; p 0.03). Diagnostic Characteristics of the T-SPOT.TB and TSTs p Value T-SPOT.TB test Unadjusted Adjusted* TST Unadjusted Adjusted BCG vaccinated only BCG unvaccinated only *Adjusted for BCG vaccination status, age, HIV status, and race/ ethnicity; p value for interaction between contact status and BCG vaccination p 0.001, contact status vs BCG vaccination; therefore, the model adjusted for age, HIV status, and race/ethnicity is presented stratified by BCG vaccination status. The diagnostic characteristics of the T-SPOT.TB and TST are shown in Table 3. The T-SPOT.TB test was more specific for contact status than the TST (75% vs 23%, p 0.001). Importantly, this difference was even more pronounced among BCGvaccinated subjects (70% vs 3%, p 0.001). In contrast, the tests had similar specificities among subjects without BCG vaccination. The T-SPOT.TB test and the TST had similar sensitivities for contact status regardless of BCG vaccination status. Among BCG-vaccinated subjects, the T-SPOT.TB test had a higher negative predictive value (50% vs 6%, p 0.002) and a higher accuracy (56% vs 35%, p 0.02). Test characteristics were similar for both tests among BCG-unvaccinated subjects. Indeterminate Results and Technical Difficulties Eight subjects had indeterminate tests. None of the eight were known to have an immunosuppressive condition and none were receiving immunosuppressive medications. Four of the eight subjects were BCG vaccinated, and six subjects were TST positive. Technical difficulties with the T-SPOT.TB test occurred in six subjects. Five subjects had excessive spots in the nil control. Only one of the five subjects was available for repeat testing, and the repeat demonstrated excessive spots in the nil control once again. One additional subject had too low a cell count for interpretation. Discussion We have demonstrated that, compared with TST, the T-SPOT.TB test has improved specificity in identifying a group of subjects at high risk for progression to active tuberculosis, namely, close contacts of cases of active tuberculosis. Our study demonstrates the superiority of the T-SPOT.TB test over the TST under routine clinical conditions in a population critical to tuberculosis control: foreignborn persons from high-prevalence countries with high rates of BCG vaccination. These findings should Table 3 Diagnostic Characteristics of the T-SPOT.TB and TST as Predictors of Close Contact Status Variables Sensitivity (95% CI) Specificity (95% CI) Positive Predictive Value (95% CI) Negative Predictive Value (95% CI) Accuracy (95% CI) Entire cohort T-SPOT.TB 45 (31 59) 75 (59 87)* 71 (54 85) 49 (36 62) 57 (47 67) TST 62 (49 75) 23 (11 38) 53 (40 65) 30 (15 49) 46 (36 56) BCG vaccinated only T-SPOT.TB 45 (29 62) 70 (50 85)* 65 (44 83) 50 (34 66)* 56 (43 68)* TST 61 (44 76) 3 (0 17) 44 (30 59) 6 (0 30) 35 (24 47) BCG unvaccinated only T-SPOT.TB 44 (21 69) 90 (56 99) 89 (52 99) 47 (24 71) 61 (41 79) TST 67 (41 87) 80 (44 97) 86 (57 98) 57 (29 82) 71 (51 87) *p 0.05 for comparison with TST. 872 Original Research
5 be widely applicable to the many outpatient clinics serving similar populations. As a recent metaanalysis 5 points out, prior studies of the T-SPOT.TB test have suggested improved specificity as compared with the TST, especially in BCGvaccinated individuals. Our study adds strength to these earlier findings by demonstrating good performance characteristics of the test in a population that included both close contacts and noncontacts. Shams et al 9 reported similar findings in a large cohort of contacts using a scoring system which had not been previously validated for determining the likelihood of being a close contact. Interestingly, our study demonstrated similar performance characteristics for the T-SPOT.TB test as in the study by Shams et al, 9 with a much simpler scheme for judging closeness of contact. Another study 10 that examined both contacts and others was largely hospital based and does not reflect routine outpatient clinical practice. The improved specificity of the T-SPOT.TB test is especially important because it could decrease unnecessary treatment in those who are not actually infected. This would avoid costs to the health-care system (as well as the individual patient) for medication, follow-up, and management of complications. Given that there is no gold standard for the diagnosis of LTBI, determining test characteristics of any novel diagnostic, as compared with the TST, becomes problematic. Specificity is something of an exception. A test could be considered superior in specificity if its results appeared to be independent of BCG vaccination status. Since BCG vaccination status is easily ascertainable by the investigator (or the clinician), a reasonable estimate of specificity may be obtained. Sensitivity is more difficult to determine. Contacts are imperfect surrogates for the diagnosis of LTBI. Because not all contacts are actually infected with M tuberculosis, it is difficult to precisely estimate the sensitivity of any new test. Nevertheless, since it is well documented that the risk of LTBI among contacts increases with increasing exposure to a source case, 4,11,12 or increasing amounts of time spent in situations of known risk for acquiring LTBI (eg, incarceration), the odds of having LTBI correlate with degree of exposure. 9,12,13 A test that is superior to the TST in sensitivity would therefore be more likely to be positive in a contact than a noncontact. Sensitivity in the context of our study therefore refers to sensitivity for contact status, and there was no statistically significant difference between the tests in their sensitivity for contact status. We found that there were fewer positive T-SPOT.TB test results than positive TST results in those deemed close contacts. However, the clinical significance of this finding is unclear and may reflect the fact that some of those who were deemed close contacts were not truly infected but had false-positive TST results due to prior BCG vaccination. To confirm that suspicion, a study similar to ours but using a largely BCG-unvaccinated population would need to be undertaken. Although no single, large study of this kind has been done, a comprehensive metaanalysis that includes smaller studies of this type concluded that the sensitivity of the IGRAs and the TST were in fact similar. 5 Another factor that may have contributed to the discrepancy is the possibility that the TST detects both new infection and remote infection in which the IGRAs may only detect the latter. The finding of a negative association between the TST and close contact status in our analysis of BCG-vaccinated subjects almost certainly reflects abundant false-positive results with skin testing in these subjects and reinforces the impression of confounding of the TST by BCG. Clearly, the strong association between the TST and contact status in subjects without BCG vaccination shows its utility in this setting. However, in BCG-vaccinated individuals, the TST appears to be highly inaccurate as a predictor of contact status. In actuality, identifying every person with LTBI is not important clinically because only a small percentage of such persons will ever go one to have active tuberculosis, and most will not benefit (and may be harmed) by treatment. A strategy aimed at identifying those with LTBI who are most at risk of progression to active TB is a useful one in evaluating a new diagnostic test. In that regard, we have shown that in a population such as ours, the T-SPOT.TB test is superior to the TST. One potential limitation of our study was the collection of blood samples for T-SPOT.TB testing regardless of the timing of TST. There is a theoretical concern that the IGRAs may be boosted by TST placement. A recent report 14 suggests that this may be an issue with the QFT but not with the T-SPOT.TB test. Other investigators 9,15 have similarly found no boosting effect with the ELISPOT test. Nonetheless, it is an issue that requires further study. Another issue that this raises is that of conversions and reversions of the TSTs during the period of time between the TST and the T-SPOT.TB test. While this window of time is rather small with regard to this phenomenon, an effect cannot be ruled out. Both the TST and the T-SPOT.TB test rely to a degree on an intact immune response. It is therefore imperative that they be tested in populations with impaired immune function, particularly in patients with HIV given the disease burden of TB in this population. In our study, we took care to avoid mixing these populations because this might have clouded the interpretation of our results. We CHEST / 133 / 4/ APRIL,
6 therefore excluded patients with known HIV. Despite this, eight subjects had indeterminate test results, defined as an inadequate response to the mitogen-positive control. Interestingly, six of the eight subjects had positive TST results (two subjects with unknown HIV status, and four subjects who were HIV negative by report), which argues against the presence of complete anergy in these subjects. However, anergy is a highly variable phenomenon, and it is possible that antigens present in the Mantoux reagent other than ESAT6 and CFP10 elicited a skin test response not provoked by the T-SPOT.TB assay. The cutoff values for the TST were interpreted according to the current guidelines as indicated in the Materials and Methods section. The results would not have been affected by stratifying the analysis using different TST size cutoffs because only two contacts were TST positive with 10 mm of induration (5 mm and 6 mm, respectively), and no noncontacts were deemed negative in the 10- to 14-mm range (low risk). Currently, the QFT is recommended by the CDC. 1 CDC recommendations do not make mention of the T-SPOT.TB test since it is not yet approved by the US Food and Drug Administration. At this time, we cannot say whether the results of this study can be extrapolated to the QFT. Further comparisons of the two tests with the TST and with each other are needed. Also, our study did not address the cost-effectiveness of the T-SPOT.TB test in this setting. However, several studies have concluded that the IGRAs are indeed likely to be cost-effective. In conclusion, we have demonstrated that compared with skin testing, the T-SPOT.TB test has greatly improved specificity in identifying a group of subjects at high risk for progression to active tuberculosis. The T-SPOT.TB test proved robust in the setting of routine outpatient clinic conditions, suggesting wide applicability. Further testing is needed in immunocompromised subjects and subjects at the extremes of age. Longitudinal studies are needed to verify the significance of a positive T-SPOT.TB test with regard to risk for active tuberculosis. ACKNOWLEDGMENT: We gratefully acknowledge the support of the Stony Wold-Herbert Fund, Inc. References 1 Taylor Z, Nolan CM, Blumberg HM. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54: Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to N Engl J Med 2002; 346: Farhat M, Greenaway C, Pai M, et al. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: Brodie D, Schluger NW. The diagnosis of tuberculosis. Clin Chest Med 2005; 26: , vi 5 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: Royal College of Physicians, Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September Am J Respir Crit Care Med 2000; 161:S221 S247 8 Screening for tuberculosis and tuberculosis infection in highrisk populations: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995; 44: Shams H, Weis SE, Klucar P, et al. Enzyme-linked Immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005; 172: Ferrara G, Losi M, D Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: Lutong L, Bei Z. Association of prevalence of tuberculin reactions with closeness of contact among household contacts of new smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2000; 4: Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: Arend SM, Thijsen SF, Leyten EM, et al. Comparison of two interferon- assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175: Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN- responses at 6 weeks following tuberculin skin testing. Eur Respir J 2007; 29: Richeldi L, Ewer K, Losi M, et al. Repeated tuberculin testing does not induce false positive ELISPOT results. Thorax 2006; 61: Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006; 28: Dewan PK, Grinsdale J, Liska S, et al. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon- assay. BMC Infect Dis 2006; 6:47 18 Diel R, Nienhaus A, Lange C, et al. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28: Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of interferon- release assay testing for the treatment of latent tuberculosis. Eur Respir J 2007; 30: Original Research
TB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationIndeterminate test results of T-SPOT TM.TB performed under routine field conditions
Eur Respir J 2008; 31: 842 846 DOI: 10.1183/09031936.00117207 CopyrightßERS Journals Ltd 2008 Indeterminate test results of T-SPOT TM.TB performed under routine field conditions P. Beffa*, A. Zellweger
More informationReceived 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007
CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 714 719 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationTitle: Comparison of an ESAT-6/ CFP-10 Peptide-Based ELISPOT Assay to Tuberculin. Skin Test for Tuberculosis Screening in a Moderate Risk Population
CVI Accepts, published online ahead of print on 18 April 2007 Clin. Vaccine Immunol. doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationInterferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis
CLINICAL AUDIT Clinical Medicine 2013, Vol 13, No 4: 362 6 Interferon gamma release assays and the NICE 2011 guidelines on the diagnosis of latent tuberculosis Helen R Mujakperuo, Richard D Thompson and
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationSilicotic subjects are at a high risk of. Comparison of T-Spot.TB and tuberculin skin test among silicotic patients
Eur Respir J 2008; 31: 266 272 DOI: 10.1183/09031936.00054707 CopyrightßERS Journals Ltd 2008 Comparison of T-Spot.TB and tuberculin skin test among silicotic patients C.C. Leung*, W.C. Yam #, W.W. Yew
More informationThe Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationIs the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center
Microbiology and Infectious Disease / QuantiFERON-TB Assay for TB Screening Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationCritical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings
Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings by John Metcalfe Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationDiagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs)
Diagnosis of tuberculosis: principles and practice of using interferon- release assays (IGRAs) Educational aims To provide an overview of interferon- release assays (IGRAs) used for detection of tuberculosis
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationInterferon-Gamma Release Assays and Pediatric Public Health Tuberculosis Screening: The San Francisco Program Experience 2005 to 2008
Original Article Interferon-Gamma Release Assays and Pediatric Public Health Tuberculosis Screening: The San Francisco Program Experience 2005 to 2008 Jennifer A. Grinsdale, 1,a Shamim Islam, 2,a Olivia
More information결핵노출접촉자감염관리 서울아산병원감염내과 김성한
결핵노출접촉자감염관리 서울아산병원감염내과 김성한 TB incidence (2012) TB incidence South Korea 108 China 73 Taiwan 68 Portucal 26 Japan 19 Spain 14 US 3.6 * unit- per 100,000 population Adapted from WHO Adapted from WHO Emerg
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationCOMPARISON OF TWO INTERFERON-G ASSAYS AND
3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationPerformance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children
616 TUBERCULOSIS Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children T G Connell*, N Curtis*, S C Ranganathan, J P Buttery...
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationTime interval to conversion of interferon-c release assay after exposure to tuberculosis
Eur Respir J 2011; 37: 1447 1452 DOI: 10.1183/09031936.00089510 CopyrightßERS 2011 Time interval to conversion of interferon-c release assay after exposure to tuberculosis S.W. Lee*,#, D.K. Oh ", S.H.
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationInterferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients
NDT Advance Access published January 22, 2009 Nephrol Dial Transplant (2009) 1 of 5 doi: 10.1093/ndt/gfn748 Original Article Interferon-gamma release assays versus tuberculin skin testing for detection
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationClinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*
CHEST Clinical Utility of the QuantiFERON -2G Test for Elderly Patients With Active Tuberculosis* Yoshihiro Kobashi, MD, PhD; Keiji Mouri, MD; Shinich Yagi, MD; Yasushi Obase, MD, PhD; Naoyuki Miyashita,
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationEPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Screening Time to Complete Exercise: 30 minutes
EPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Time to Complete Exercise: 30 minutes LEARNING OBJECTIVES At the completion of this Case Study, participants should be
More informationRichard N. van Zyl-Smit 1, Rannakoe J. Lehloenya 1,2, Richard Meldau 1, Keertan Dheda 1,3,4. Introduction
Original Article Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT. TB and QFT-GIT) Richard N. van Zyl-Smit
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationCoordinating with Public Health on Tuberculosis Testing & Treatment
Coordinating with Public Health on Tuberculosis Testing & Treatment Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Associate Professor University of New Mexico College of Pharmacy Objectives 1. Identify
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationTherapy for Latent Tuberculosis Infection
Screening and Treatment of LTBI in TB Control in the US Margarita Elsa Villarino MD MPH Division of TB Elimination, CDC April 14, 2004 TB Prevention and Control in the United States The fundamental strategies
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationInvestigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00730-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Investigation of false-positive
More informationThe Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers
ORIGINAL ARTICLE The Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers Masaki Tanabe 1, Akiko Nakamura 1, Akie Arai 1, Daisuke Yamasaki
More informationInterferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients
Interferon- Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis Patients Kevin L. Winthrop,* Melissa Nyendak, Helene Calvet, Peter Oh, Melanie Lo, Gwendolyn Swarbrick,
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationWithin-Subject Variability of Mycobacterium tuberculosis-specific Gamma Interferon Responses in German Health Care Workers
CLINICAL AND VACCINE IMMUNOLOGY, July 2011, p. 1176 1182 Vol. 18, No. 7 1556-6811/11/$12.00 doi:10.1128/cvi.05058-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Within-Subject
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More information2. Methods of Tuberculosis Screening
2. Methods of Tuberculosis Screening Diagnosis of active or latent TB involves a number of tests. There is no gold standard for determining whether a person is infected with M. tuberculosis but in practice
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested
More informationClinical Policy Title: Interferon-gamma release assays for tuberculosis screening
Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening Clinical Policy Number: 07.01.06 Effective Date: March 1, 2014 Initial Review Date: November 20, 2013 Most Recent Review
More informationSummary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationEvaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1089 1093 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1089 1093.2004 Copyright 2004, American Society for Microbiology. All
More information